AstraZeneca partners with Quell Therapeutics to develop engineered Treg cell therapies
Under the agreement, AstraZeneca will harness Quell's distinctive arsenal of Treg cell engineering modules, which includes the groundbreaking…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Jun 23
Under the agreement, AstraZeneca will harness Quell's distinctive arsenal of Treg cell engineering modules, which includes the groundbreaking…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
09 Jun 23
Certest, a company specialized in the development, manufacturing, and commercialization of solutions for the diagnosis of infectious diseases,…
08 Jun 23
The EC authorisation follows the positive recommendation by the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
08 Jun 23
Invistics’ Flowlytics solution utilises predictive analytics to identify illicit diversion of both controlled and non-controlled medications in patient…
07 Jun 23
Together with its gene therapy unit AskBio, Bayer will access Acuitas’ high-potency ionisable lipid technology and LNP carriers,…
07 Jun 23
The new range of products is intended to help researchers to tap into the potential of birth tissues…
07 Jun 23
Curi Bio has designed the MantaReady iPSC-derived skeletal muscle myoblasts for preclinical therapeutic discovery, high-throughput screening, and disease…
07 Jun 23
The new facility will be the eighth in Colorcon's global network; and will produce high-quality and innovative film…
07 Jun 23
This strategic move will help CitiusTech expand its global delivery model through its foray into the European market,…
07 Jun 23
Scheduled to open in July 2023, the new regional commercial office located in Minato, Tokyo, will be part…